Trial Profile
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2012
Price :
$35
*
At a glance
- Drugs EC 0489 (Primary) ; Technetium Tc99m etarfolatide
- Indications Cancer
- Focus Adverse reactions
- 07 Aug 2012 Actual end date Apr 2012 added as reported by ClinicalTrials.gov.
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.